USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 10, 2022 | Sep 2022 | - | - | $-1.09 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 10, 2022 | Sep 2022 | - | - | $0.00 |
Applied Therapeutics's next earnings date is Thursday, Nov 10, 2022 for the fiscal quarter ending Sep 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 6 | $-3.23 | $-4.18 | $-2.32 |
| Dec 2023 | 6 | $-2.76 | $-4.45 | $-1.54 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 4 / 0 | $-4.11 | $-3.97 | $-4.54 |
| Dec 2023 | 4 / 0 | $-3.60 | $-3.38 | $-3.77 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 5 | $1.12M | $0.00 | $3.00M |
| Dec 2023 | 5 | $12.08M | $0.00 | $58.00M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 10, 2022 | Jun 2022 | $-0.78 | - | - |
| May 12, 2022 | Mar 2022 | $-0.83 | $-0.88 | -6.02% |
| Mar 10, 2022 | Dec 2021 | $-1.25 | $-1.04 | 16.80% |
| Nov 12, 2021 | Sep 2021 | $-1.16 | $-1.09 | 6.03% |
| Aug 12, 2021 | Jun 2021 | $-1.13 | $-0.99 | 12.39% |
| May 11, 2021 | Mar 2021 | $-1.01 | $-1.00 | 0.99% |
| Mar 18, 2021 | Dec 2020 | $-1.25 | $-1.06 | 15.20% |
| Nov 12, 2020 | Sep 2020 | $-1.02 | $-1.33 | -30.39% |
| Aug 11, 2020 | Jun 2020 | $-0.69 | $-1.27 | -84.06% |
| May 11, 2020 | Mar 2020 | $-0.82 | $-0.59 | 28.05% |
| Mar 13, 2020 | Dec 2019 | $-0.64 | $-1.57 | -145.31% |
| Nov 13, 2019 | Sep 2019 | $-0.49 | $-0.63 | -28.57% |
| Aug 12, 2019 | Jun 2019 | $-0.49 | $-0.60 | -22.45% |
| May 14, 2019 | Mar 2019 | $-0.40 | $-1.58 | -295.00% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 10, 2022 | Dec 2021 | $-4.38 | $-4.12 | - |
| Mar 18, 2021 | Dec 2020 | $-4.53 | $-4.25 | - |
| Mar 13, 2020 | Dec 2019 | $-3.00 | $-4.38 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 10, 2022 | Jun 2022 | $0.00 | - | - |
| May 12, 2022 | Mar 2022 | $0.00 | $0.00 | - |
| Mar 10, 2022 | Dec 2021 | $0.00 | $0.00 | - |
| Nov 12, 2021 | Sep 2021 | $0.00 | $0.00 | - |
| Aug 12, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| May 11, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Mar 18, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Nov 12, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 11, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| May 11, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Mar 13, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Nov 13, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 12, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| May 14, 2019 | Mar 2019 | $0.00 | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 10, 2022 | Dec 2021 | $0.00 | $0.00 | - |
| Mar 18, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Mar 13, 2020 | Dec 2019 | $0.00 | $0.00 | - |
APLT's next earnings date is Thursday, Nov 10, 2022 for the fiscal quarter ending Sep 30, 2022.
Applied Therapeutics's previous earnings date was Aug 10, 2022 for its fiscal quarter ended Jun 30, 2022.
Applied Therapeutics's previous annual earnings date was Mar 10, 2022 for its fiscal year ended Dec 31, 2021.
APLT's earnings per share (EPS) was $-4.12, beating the consensus analysts forecast of $-4.38 by -5.94% , and higher than the previous year's EPS (Dec 2020) by -3.06%.
Revenues were $0.00.
The company reported a net income of $-105.58M.
Applied Therapeutics reported a free cash flow of $-90.73M for its fiscal year, compared to $-78.21M a year ago.
The company ended the fiscal year with $1.33M in total debt, a decrease of -52.60% compared to the previous year.
